Information on the current vaccine scandal in China – how does this affect Germany?
The Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, offers FAQs on the current vaccine scandal.
Is it possible that the Changchun Changsheng Company exported vaccines to Germany?
No. All vaccines marketable in Germany either have a national marketing authorisation granted by the Paul-Ehrlich-Institut (PEI) or a so-called centralised marketing authorisation from the EU Commission granted in a procedure by the European Medicines Agency (EMA). The centralised marketing procedure is valid in all EU member states (plus Norway and Iceland). The vaccines manufactured or marketed by the Chinese company Changchun Changsheng have neither a national nor a centralised EU marketing authorisation.
Is there a possibility that marketing authorisation holders who market vaccines in Germany have manufacturing sites in China?
No. None of the marketing authorisation holder has a manufacturing site in China or purchases antigen components from China for the vaccines authorised in Germany or in the EU.
How can I be sure that the vaccine which I receive will contain an effective component?
Vaccines are subject to official batch testing. After in-house controls at the manufacturer, the PEI – or another recognized official testing laboratory for the examination and independent quality control of medicines from another European country also performs experimental batch control tests on the samples to be tested from the vaccine batches. During these tests, the PEI would identify any vaccines that do not contain an antigen component, i.e. an active ingredient, such as the Chinese rabies vaccines about which the media reported. Patients in Germany can be sure that the vaccines administrated in Germany and the EU are safe and effective.